Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), announced a strategic partnership with The Nucleus Network, a fast-growing community for founders, investors, executives, and innovators. Flyte will support and participate in the inaugural “The Nucleus” flagship event on August 15 at 4:00 p.m..
The event is intended to become The Nucleus Network’s signature annual gathering, convening about 200 founders, investors, operators, and strategic partners for networking, brand activations, and relationship building. According to Flyte, this partnership aligns with its strategy to connect with influential entrepreneurial and venture communities while promoting its technology-enabled private aviation services and growing fleet of Cirrus Vision Jets.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), reported preliminary record monthly revenue of approximately $640,000 for July 2026, a 102% sequential increase over June, marking the strongest operating month in Flyte’s history as demand rises on its private aviation platform.
Since relaunching its direct-to-consumer platform, Flyte has added 2,700+ new users, supported by strategic partnerships, digital marketing, and influencer campaigns. In 2026 it expanded partnerships with Blade, Vaunt, Volato AI (NYSE American: SOAR), GSE Worldwide & Emiliano Grillo, LifeVac, and LDV at The Maidstone. Catheter Precision emphasized that June and July 2026 revenue figures are preliminary, unaudited estimates and remain subject to change.
Catheter Precision (NYSE American: VTAK), through its subsidiary Flyte, announced that Flyte has become the inaugural enterprise customer of Volato AI (NYSE American: SOAR), an aviation-focused enterprise artificial intelligence platform. The deployment is intended to support Flyte’s strategy of building a scalable regional private aviation platform using advanced technology and intelligent automation.
According to Catheter Precision, Volato AI is expected to assist Flyte across multiple operational workflows, including customer communications, charter sales support, flight quoting, crew coordination, maintenance scheduling, dispatch support, compliance assistance, document management, operational scheduling, and broader administrative workflow automation. Flyte expects AI to enhance customer responsiveness, automate repetitive tasks, increase employee productivity, and improve operating leverage as short-haul private aviation activity grows.
Volato Group (NYSE American: SOAR) announced the commercial launch of Volato AI, a purpose-built enterprise AI platform for business aviation, and its first enterprise deployment with Flyte, a regional air mobility company owned by Catheter Precision (NYSE American: VTAK). The aviation-specific AI agents are designed to increase employee productivity, improve customer responsiveness, reduce administrative workload, and help operators scale Part 135 charter operations without proportional overhead growth.
The initial Flyte deployment will cover workflows such as customer communications, charter sales support, flight quoting, crew coordination, maintenance scheduling, dispatch support, compliance assistance, document management, and administrative automation. Volato emphasized that its pending AI infrastructure business combination remains the company’s primary strategic focus and is still subject to due diligence, definitive agreements, and regulatory and exchange requirements.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), announced a strategic partnership with LDV at The Maidstone, a historic luxury boutique hotel in East Hampton. The agreement gives Maidstone guests exclusive preferred pricing on Flyte’s private aviation services for travel to and from the Hamptons.
According to Flyte, the collaboration is intended to integrate private air travel into the overall guest experience and support its strategy to become a leading transportation partner in the Hamptons. Flyte highlights its technology-enabled booking platform, standardized pricing on select routes, and a growing fleet of Cirrus Vision Jets serving Northeast leisure destinations.
Flyte (NYSE American: VTAK), the technology-enabled Regional Air Mobility subsidiary of Catheter Precision, announced a strategic partnership with 319 Golf Society, which has members from over 70 of the top 200 U.S. private golf clubs. Flyte is named the Society’s Exclusive Private Aviation Partner.
According to the company, 319 Golf Society members receive $1,000 toward their first Flyte trip, exclusive merchandise, member gifts, and access to Flyte events and promotions. The deal targets golfers who frequently travel between private clubs, resorts, business meetings, and second homes using Flyte’s Cirrus Vision Jet fleet operated by its FAA-certified carrier Ponderosa Air.
Flyte (NYSE American: VTAK), the regional air mobility subsidiary of Catheter Precision, announced a non-exclusive strategic partnership with Blade Urban Air Mobility. Under the agreement, Flyte’s Cirrus Vision Jet fleet and charter offerings will be featured on Blade’s platform, giving Blade passengers access to Flyte’s fixed-price, technology-enabled short-haul private aviation services across the United States.
According to Flyte, the deal is expected to broaden its distribution, increase booking opportunities, and raise brand awareness among premium, time-sensitive regional travelers already using app-based air mobility. Flyte highlights its scalable operating platform, safety-focused Cirrus Vision Jet fleet, and ongoing strategy of growth through partnerships, fleet expansion, technology integration, and consumer awareness initiatives.
Flyte, the Regional Air Mobility subsidiary of Catheter Precision (NYSE American: VTAK), announced a strategic, non-exclusive partnership with Blade Urban Air Mobility to feature Flyte's Cirrus Vision Jet fleet and charter offerings on Blade's platform. Blade users will gain access to Flyte's modern, efficient regional private aviation solution, while Flyte expects increased booking opportunities, aircraft utilization, customer acquisition, and brand awareness among premium, time-sensitive travelers.
According to Flyte, this partnership supports its strategy to build a scalable regional air mobility platform through strategic partnerships, fleet expansion, technology integration, and consumer-awareness initiatives, and further validates its regional air mobility model within Blade's ecosystem.
Catheter Precision (NYSE American: VTAK) reported preliminary unaudited record revenue of $1,037,000 for the quarter ended June 30, 2026, combining its MedTech and Flyte Vision Jet segments. The Flyte Vision Jet segment generated $767,000, up 61% sequentially over Q1 2026, while the MedTech segment grew 27% over Q2 2025.
According to the company, preliminary revenue for the first two weeks of July 2026 exceeded $400,000. Catheter Precision is also working with an outside investment bank to evaluate alternative scenarios for its MedTech segment and aims to finalize related plans over the next several months.
Flyte (NYSE American: VTAK), the Regional Air Mobility arm of Catheter Precision, announced a partnership with LifeVac to place LifeVac airway clearance devices on every Cirrus Vision Jet in its fleet.
This extends Flyte’s standardized, Vision Jet–based safety ecosystem to include onboard medical emergency preparedness for choking incidents.